Alpharmaxim full lockup logo

Genome sequencing is the future for rare diseases

Maintaining the voice of rare diseases in a new, virtual world: Insights from the European Conference on Rare Diseases (ECRD) 2020

Genome sequencing is the future for rare diseases

Public engagement and education are key to the successful implementation and uptake of genome sequencing. Alpharmaxim develop scientific materials and activities that are built upon compelling stories, to support engaging educational programmes.

  • In the future, whole-genome sequencing that can test for over 800 disorders may be used. There is currently research ongoing in this area
  • Clinics, however, are unable to access genomic data
  • It is estimated that only 30% of rare disease patients could be potentially diagnosed with AI tools, and only then, if they have a genetic background
  • Unfortunately, 60% of people remain undiagnosed because there are multiple genes involved
  • We need to improve clinical management, treatment options and quality of life for children and families
  • While technical analysis is no longer the rate-limiting step, we should be looking at genome sequencing and analysis to help with the surveillance and long-term follow-up of patients with rare diseases

Be prepared to truly demonstrate your commitment to the rare disease field, particularly in these uncertain times.

Talk to us about how we can transform your communications

Why Plain Language Summaries are vital in rare disease communications

Why Plain Language Summaries are vital in rare disease communications

Plain language summaries can translate complex science for different audiences. But what are they, and how do they improve awareness?
What can COVID-19 campaigns tell us about increasing vaccine uptake?

What can COVID-19 campaigns tell us about increasing vaccine uptake?

We examine what lessons we can take from the COVID-19 vaccine campaigns, and how behavioural science insights may help to drive vaccine uptake.
Transforming the rare disease landscape

Transforming the rare disease landscape

Over the coming months, we’ll be looking at how new, tailored approaches to communications could help transform the rare disease landscape.